Regenxbio Inc., a gene-therapy firm that creates adeno-associated viruses, which are designed to get inside genes and change mutations that cause disease, started trading on NASDAQ on September 17. Regenxbio was cofounded by Dr. James Wilson, director of the Gene Therapy Program and the Orphan Disease Center at Penn. The company went public through a $138.6 million initial public offering (IPO).
Philadelphia Business Journal coverage.
Genetic Engineering & Biotechnology News (GEN) coverage.